Evidence map›Paper›PMID 32166037›Full record

ArticleBasic and clinical andrology2020

Efficacy of relaxin for cisplatin-induced testicular dysfunction and epididymal spermatotoxicity.

Tetsuya Kohsaka, Itaru Minagawa, Masashi Morimoto, Takuya Yoshida, Tomohiro Sasanami, Yoshitaka Yoneda, Naoki Ikegaya, Hiroshi Sasada

Open access · goldAbstract read
In one paragraph

Article in Basic and clinical andrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Testicular toxicity of cisplatin in rats: ameliorative effect of lycopene and N-acetylcysteine.Environmental science and pollution research international · 2022
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Tetsuya Kohsaka1Department of Applied Life Sciences, Animal Reproduction & Physiology Faculty of Agriculture, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529 Japan.ORCID 0000-0001-9093-8243
Itaru Minagawa1Department of Applied Life Sciences, Animal Reproduction & Physiology Faculty of Agriculture, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529 Japan.
Masashi Morimoto1Department of Applied Life Sciences, Animal Reproduction & Physiology Faculty of Agriculture, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529 Japan.
Takuya Yoshida2Department of Clinical Nutrition, School of Food and Nutritional Science, University of Shizuoka, Shizuoka, 422-8526 Japan.
Tomohiro Sasanami1Department of Applied Life Sciences, Animal Reproduction & Physiology Faculty of Agriculture, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529 Japan.
Yoshitaka YonedaAdvanced Reproductive Medical Center, Shizuoka Ladies Clinic, Shizuoka, 420-0837 Japan.
Naoki IkegayaDepartment of Medicine, Yaizu Municipal General Hospital, Shizuoka, 422-8505 Japan.
Hiroshi Sasada5Division of Animal Science, Kitasato University School of Veterinary Medicine, Towada, 034-8628 Japan.
Shizuoka University · JPKitasato University · JPShizuoka General Hospital · JPShizuoka Medical Center · JPUniversity of Shizuoka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCisplatin (CP) is an extremely effective anticancer agent widely used to treat various cancer types, however, the potential side effects include testicular dysfunction. This study was to investigate, using a rat model of CP-induced testicular dysfunction, the protective effects of relaxin (RLN) against oxidative stress, testicular function, histological damage, spermatogenesis, germ-cell apoptosis, and sperm output, and to explore the usefulness of RLN as a potential protective drug for use with CP in chemotherapeutic treatments.

methodsSprague-Dawley male rats were used, which were divided into three groups: sham control, CP, and CP + RLN. Porcine RLN (500 ng/h) or saline was infused for 5 days using an implanted osmotic mini-pump following intraperitoneal injection of CP (6 mg/kg). RLN dose was chosen based on previous studies showing that it resulted in serum relaxin levels comparable to those in rats at the middle of pregnancy. At 5 days after CP administration, samples were collected and assessment of testicular histopathology, germ-cell apoptosis, oxidative stress, lipid peroxidation, and sperm quality was performed as main measures.

resultsThe testicular CP model showed reduced testis weight and significantly decreased spermatogenesis scores. Additionally, CP administration induced a 4.6-fold increase in the apoptotic index associated with a significant increase in oxidative stress and upregulation of pro-apoptotic

conclusionsThis study clearly indicates that RLN exerts a protective effect against CP-induced testicular damage through attenuation of oxidative stress and suppression of apoptosis. Our findings suggest RLN as a potentially efficacious drug for use with cisplatin chemotherapy in order to ameliorate CP-induced side effects and testicular injury adversely affecting spermatogenesis, sperm quality, and oxidative-stress parameters.

Indexed as

Anti-apoptotic effectAntioxidant effectCisplatinRelaxinSide effectTesticular dysfunction

Identifiers

PMID32166037
PMCPMC7061478
OpenAlexW3011876938

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.